Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ODAC Unanimously Recommends GSK’s Promacta For ITP

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA, committee members struggle to find ways to discourage long-term use of the drug for the chronic condition.

You may also be interested in...



GSK’s Promacta And Amgen’s Nplate Face Off In ITP Market

GlaxoSmithKline/Ligand's Promacta (eltrombopag) received FDA approval Nov. 20 as a second-line treatment of thrombocytopenia in patients with the rare blood disorder chronic idiopathic thrombocytopenic purpura. The approval was widely anticipated, although it came five months after the drug's original PDUFA date

GSK’s Promacta And Amgen’s Nplate Face Off In ITP Market

GlaxoSmithKline/Ligand's Promacta (eltrombopag) received FDA approval Nov. 20 as a second-line treatment of thrombocytopenia in patients with the rare blood disorder chronic idiopathic thrombocytopenic purpura. The approval was widely anticipated, although it came five months after the drug's original PDUFA date

GSK’s Promacta And Amgen’s Nplate To Face Off In ITP Market

GlaxoSmithKline’s thrombocytopenia treatment for patients with idiopathic thrombocytopenic purpura will launch the week of Nov. 24.

Related Content

Topics

UsernamePublicRestriction

Register

PS067843

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel